Suscribirse

Predictors of type 2 diabetes relapse after Roux-en-Y Gastric Bypass: A ten-year follow-up study - 15/02/22

Doi : 10.1016/j.diabet.2021.101282 
D. Moriconi a, M.L. Manca b, M. Anselmino c, E. Rebelos b, R. Bellini c, S. Taddei b, E. Ferrannini d, M. Nannipieri b, ⁎
a Dpt. Surgical, Medical, Molecular Pathology and Critical Care Medicine,University of Pisa, Italy 
b Dpt.Clinical and Experimental Medicine, University of Pisa, Via Savi 10, 56126 Pisa, Italy 
c Bariatric Surgery Unit. Azienda Ospedaliera Universitaria Pisana, Pisa, Italy 
d Institute of Clinical Physiology, National Research Council (CNR), Pisa, Italy 

⁎Corresponding author.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Highlights

•
Roux-en-Y Gastric Bypass significantly reduced and sustained glycated haemoglobin (HbA1c) levels compared to medical therapy at ten-year follow-up.
•
The short duration of diabetes is of fundamental importance to achieve long-term remission of diabetes after bariatric surgery.
•
Weight loss impacts the short-term remission of type 2 diabetes, but has a marginal role in long-term relapse.

El texto completo de este artículo está disponible en PDF.

Abstract

Aims

: To assess the impact of bariatric surgery on remission and relapse of type 2 diabetes mellitus (T2DM) at 10 years of follow-up and analyze predictive factors.

Materials and Methods

: Eighty-eight obese subjects undergoing Roux-en-Y gastric bypass (RYGB) and 25 subjects assigned to medical therapy (MT) were evaluated every year for 10 years. T2DM remission was defined by the American Diabetes Association criteria.

Results

: Body mass index (BMI), fasting glucose, and haemoglobin A1c (HbA1c) improved more markedly in RYGB than MT patients throughout the 10-year period. Post-surgery remission rates were 74% and 53% at 1 and 10 years, respectively, while remission did not occur in MT patients. One-year post-surgery, BMI decreased more in subjects with remission than in those without, but no further decrease was observed thereafter. By partial-least-squares analysis, T2DM duration, baseline HbA1c, and ensuing insulin therapy were the strongest predictors of remission. Remission was achieved at one year in 91% of patients with T2DM duration < 4 years, and 79% of them remained in remission at 10 years. On the contrary only 42% of patients with T2DM duration ≥ 4 years achieved remission, which was maintained only in 6% at the end of 10 years. By survival analysis, patients with T2DM duration < 4 years had higher remission rates than those with duration ≥ 4 years (hazards ratio (HR) 3.1 [95%CI 1.8–5.7]). Relapse did not occur before two years post-surgery and was much less frequent in patients with < 4- vs ≥ 4-year duration (HR 11.8 [4.9–29.4]).

Conclusions

: Short T2DM duration and good glycemic control before RYGB surgery were the best requisites for a long-lasting T2DM remission, whereas weight loss had no impact on the long-term relapse of T2DM.

El texto completo de este artículo está disponible en PDF.

Keywords : Bariatric surgery, Diabetes relapse, Gastric Bypass, Obesity, Type 2 diabetes mellitus, Weight loss


Esquema


© 2021  Elsevier Masson SAS. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 48 - N° 1

Artículo 101282- janvier 2022 Regresar al número
Artículo precedente Artículo precedente
  • Transitions in metabolic health status over time and risk of heart failure: A prospective study
  • Jianing Bi, Lulu Song, Lulin Wang, Binbin Su, Mingyang Wu, Dankang Li, Shuohua Chen, Yunyun Liu, Yingping Yang, Ziyi Zhou, Yonghua Hu, Youjie Wang, Shouling Wu, Yaohua Tian
| Artículo siguiente Artículo siguiente
  • Use of DPP4i reduced odds of clinical deterioration and hyperinflammatory syndrome in COVID-19 patients with type 2 diabetes: Propensity score analysis of a territory-wide cohort in Hong Kong
  • Carlos K.H. Wong, David T.W. Lui, Angel Y.C. Lui, Ashley C.Y. Kwok, Marshall C.H. Low, Kristy T.K. Lau, Ivan C.H. Au, Xi Xiong, Matthew S.H. Chung, Eric H.Y. Lau, Benjamin J. Cowling

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.